BBL will gain Viatris’ global biosimilars business whose revenues are estimated to be USD 1 billion next year, along with its portfolio of in-licensed biosimilar assets
The products are based on a combination of mushrooms and cannabinoids that have achieved a strong therapeutic effect using low concentrations of THC. The treatment is expected to be launched in Israel, US and UK in H2 2022
In this role, Jeffrey DeAlmeida takes responsibility for BASF’s global pharmaceutical solutions portfolio and the Nutrition & Health business in North and South America
The bulk drug plants that have already been commissioned include CDA, para amino phenol, atorvastatin, sulfadiazine, oxcarbazepine, levofloxacin, carbidopa and levodopa
Tamper evident caps with incorporated RFID technology offer a significant reduction in RFID implementation costs
Industry leaders discusses the need of innovation for the Indian drug industry at BioAsia 2022.
The facility is spread across 215000 sq. feet and provides super-speciality care
This policy will ensure multi-disciplinary collaboration, promote start-up culture and develop an innovation-led ecosystem at medical institutes across the country
PSCI, a global non-profit organization, works with its members to ensure a positive environment that can improve global healthcare supply chains
Medicago and GSK collaborated on Covifenz, an adjuvanted plant-based vaccine
Subscribe To Our Newsletter & Stay Updated
